Sign In

Brita Belli

Nerd Translator

Brita Belli is a seasoned communications professional with an impressive background in Public Relations (PR), media relations, and strategic communications in the fields of tech, biotech, and academia.

She currently holds the position of Senior Manager of Communications at Recursion, a prominent TechBio company that specializes in using automation, new biological tools, and Artificial Intelligence (AI) to decode biology and enhance lives.

Prior to her role at Recursion, Brita served as the Head of PR for Insilico Medicine, a company focused on AI drug discovery, where she successfully managed media coverage and social engagement strategies.

With a background in journalism and editing, Brita's work has been showcased in reputable publications like the New York Times, National Geographic, and MSN.com. She has also authored acclaimed books such as The Autism Puzzle and a digital playbook titled Elevating Women in Entrepreneurship.

Brita's academic journey includes a Bachelor of Arts (BA) degree in English-writing from Fairfield University, providing her with a strong foundation for her writing and communications career.

Throughout her career, Brita has been actively involved in fostering diversity, equity, and inclusion initiatives, having led communications for the Yale School of Medicine Office of Diversity and various other departments and centers at Yale University.

She has also been instrumental in promoting innovation and entrepreneurship at Yale, collaborating with academia, investment firms, and biotech companies to drive forward Yale's initiatives in these areas.

Brita's diverse professional experiences ranging from editorial roles to communications management have equipped her with a rich skill set encompassing PR, media relations, social media strategy, and project management.

Highlights

May 23 · linkedin

Pharma is leaning in on quantum computing.

A new article in Nature Biotech by Anita Chandran explores how pharma is turning to quantum computing to drive the next era of drug discovery and development. Some highlights:

◾ Merck, Johnson & Johnson, Roche and Amgen all filed patents related to quantum computing last year.

◾ Pfizer and IBM collaborated on integrating generative AI and quantum computing to improve clinical trial performance and speed results — including predicting trial sites likely to fail in recruitment.

◾ In order to scale up the processing power of quantum computers to a usable level, however, they need to be made error resistant. "When a qubit is in a superposition state of ones and zeroes, it is susceptible to noise," she writes, "which can transform it back into a classical bit."

◾ The Novo Nordisk Foundation awarded $200 million to the University of Copenhagen (Københavns Universitet) in 2022 to build a usable quantum computer and created the Danish Centre for AI Innovation with NVIDIA this past March to house one of the world’s most powerful AI supercomputers, which, she writes "will be instrumental in developing fault-tolerant quantum computing relying on NVIDIA’s CUDA-Q, an open-source hybrid quantum computing platform."

◾ There are many more collaborations underway -- Quantinuum and Amgen, QC Ware and IBM, and IBM and the Cleveland Clinic which launched IBM Quantum System One focused exclusively on health applications.

◾ Biotechs are getting in the race, too. Insilico Medicine worked with a consortium including Acceleration Consortium, Foxconn and Zapata AI to demonstrate the potential advantages of quantum generative adversarial networks in generative chemistry. https://lnkd.in/eN92kwfq

*Full Nature Biotech article here: https://lnkd.in/erPFgn_E

#ai #genai #quantum #drugdiscovery #pharma #biotech

Mar 12 · linkedin

Excellent analysis from David Berreby on why AI drug discovery is an entirely different proposition than AI for text generation. As he writes, “But if an AI working in human biology makes up a gene or a protein that doesn't exist, it's game over for that assertion. Because nothing can be done with it. You can relate words to other words regardless of their truth. But you can't make a drug that targets a gene that isn't really there.”

Check out his Robots for the Rest of Us blog and more about Insilico Medicine’s latest Nature Biotech paper on our lead AI-discovered and designed treatment for IPF in Phase II trials. (Link in comments).

#ai #drugdiscovery

Brita Belli
Add to my network

Location

Fairfield, Connecticut, United States